Investigating immune cells and proteins to understand sarcoidosis severity
Using high T-bet-expressing cells and Serum Chemokines as Indicators of Disease Severity in Sarcoidosis
This study is looking at how certain immune cells and proteins in your blood relate to the severity of sarcoidosis and how well your lungs are working, so we can better understand the disease and improve treatment for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10897084 on NIH RePORTER |
What this research studies
This research focuses on sarcoidosis, a disease that can affect multiple organs, particularly the lungs. It aims to identify specific immune cells and proteins that correlate with the severity of the disease and lung function in patients. By analyzing blood markers linked to inflammation, the study seeks to provide better insights into the disease's progression and treatment responses. Patients will be monitored over time to gather data on these immune markers and their relationship to clinical outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sarcoidosis, particularly those experiencing varying degrees of lung involvement.
Not a fit: Patients with other respiratory conditions or those without a diagnosis of sarcoidosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for assessing disease severity in sarcoidosis, potentially guiding more effective treatment strategies.
How similar studies have performed: Previous research has shown promise in using immune markers to assess disease severity in other conditions, suggesting potential for success in this novel approach for sarcoidosis.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Arger, Nicholas Kostandinos — University of California, San Francisco
- Study coordinator: Arger, Nicholas Kostandinos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.